New cancer drug trial targets specific genetic flaws
NCT ID NCT07361562
Summary
This early-stage study is testing a new oral drug called CGT4255 in adults with advanced solid tumors that have specific genetic changes (ERBB2 alterations or HER2 overexpression). The main goals are to find a safe dose and see if the drug can shrink tumors, including those that have spread to the brain. The study is recruiting about 100 people with cancers like certain types of breast cancer and lung cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
NEXT Oncology Texas
RECRUITINGAustin, Texas, 78758, United States
-
NEXT Oncology Virginia
RECRUITINGFairfax, Virginia, 22031, United States
-
NYU Langone
RECRUITINGNew York, New York, 10016, United States
-
START Midwest
RECRUITINGGrand Rapids, Michigan, 49546, United States
-
START Mountain Region
RECRUITINGWest Valley City, Utah, 84119, United States
-
Tennessee Oncology
RECRUITINGNashville, Tennessee, 37203, United States
Conditions
Explore the condition pages connected to this study.